Cevimeline and pilocarpine are muscarinic agonists used clinically to treat dry mouth. In this study, we explored fluid secretion from mouse submandibular glands to determine the mechanism of cevimeline, pilocarpine, and an experimentally used agent carbachol. Cevimeline evoked almost the same amount of secretion at concentrations from 30 M to 1 mM. Pilocarpine also induced secretion at a concentration as low as 1 M and was the most powerful secretagogue at 10 M. Secretion was induced by carbachol at 0.1 M, with maximum secretion at 1.0 M. Cevimeline induced monophasic secretion at all concentrations tested, whereas higher concentrations of pilocarpine and carbachol induced secretion with variable kinetics, i.e., an initial transient high flow rate, followed by decreased secretion after 2 to 3 min. In the presence of an epithelial Na ϩ channel blocker, amiloride, neither carbachol nor pilocarpine affected the Na ϩ level of secreted saliva; however, it significantly increased the Na ϩ content of cevimeline-induced saliva. The intracellular Ca 2ϩ response of acinar cells was almost identical among all three agents, although recovery after drug removal was slower for cevimeline and pilocarpine. A profound decrease in intracellular pH was observed during pilocarpine and carbachol treatment, whereas intracellular acidification induced by cevimeline was only seen in the presence of a Na ϩ /H ϩ exchange inhibitor. When external HCO 3 Ϫ was removed, cevimeline-induced saliva significantly decreased. These findings suggest that cevimeline specifically activates Na ϩ /H ϩ exchange and may promote Na ϩ reabsorption by stabilizing epithelial sodium channel activity.
Introduction
Salivary gland hypofunction induces dry mouth, which results in loss of not only oral health-related quality of life but also general health. The salivary glands are innervated by both sympathetic and parasympathetic pathways, with parasympathetic muscarinic receptors being the most important for control of salivary fluid secretion (Melvin et al., 2005) . Systemic muscarinic drugs for patients with severe dry mouth, such as those with Sjögren's syndrome and those who have undergone irradiation, are used in addition to supportive therapy for dry mouth.
Cevimeline (CVL) is a rigid analog of acetylcholine and is used clinically for the treatment of dry mouth. CVL induces salivation mainly through the activation of muscarinic M3 acetylcholine receptors (AChRs) on salivary acinar cells. In animal studies, CVL evoked salivation in a dose-dependent manner. This secretion was completely inhibited by atropine, a muscarinic AChR antagonist, and 4-diphenylacetoxy-Nmethyl-piperidine methiodide, an M3 AChR antagonist (Iwabuchi and Masuhara, 1994) . The binding affinity of M3 receptors for CVL is thought to be the same as or higher than affinities for other muscarinic drugs (Iga et al., 1998) . Furthermore, CVL has been shown to increase salivary secretion in both healthy subjects and patients being treated for dry mouth, including patients with Sjögren's syndrome and patients after radiotherapy for head and neck cancer (Fife et al., 2002; Chambers et al., 2007; Braga et al., 2009) . CVL is reported to be effective with oral administration as well as with gargling before swallowing to directly activate minor and major salivary glands (Takagi et al., 2004) .
Another muscarinic agonist used clinically is pilocarpine (PLC), an alkaloid imidazole obtained from the leaves of Pilocarpus jaborandi. PLC activates M3 AChRs and enhances fluid secretion from salivary tissue in a dose-dependent manner (Omori et al., 2003) . It is used clinically to induce saliva secretion in patients with Sjögren's syndrome, patients after radiotherapy, and patients with graft-versushost disease-induced dry mouth (Greenspan and Daniels, 1987; Rieke et al., 1995; Berk, 2008) . Clinical and animal studies comparing these two muscarinic drugs have revealed that although CVL requires a higher dose, it has minimal adverse effects and a longerlasting salivation effect than PLC (Masunaga et al., 1997; Braga et al., 2009) . However, most reports on CVL lack mechanistic details, and the differences between these agonists have not been well characterized at the cellular or glandular level. (Nauntofte, 1992) . It has been reported that pH i affects epithelial Na ϩ channel (ENaC) activity, which regulates Na ϩ reabsorption (Reddy et al., 2008) . In the present study, we focused on the effects of CVL and PLC, as well as those of carbachol (CCh), a muscarinic agonist used experimentally, on the secretion and ion composition of saliva, the alteration of intracellular pH, and the mechanism of cellular signaling.
Materials and Methods
Ex Vivo Mouse Submandibular Gland Analysis. All experiments were approved by the Animal Committee of Kyushu Dental College. C57BL/6J mice aged 7 to 9 weeks, purchased from the Kyushu Animal Laboratory, were habituated, and experiments were performed with the mice at 8 to 10 weeks of age. In the mouse facility, mice were exposed to a 12-h light/dark cycle and fed ad libitum. To eliminate neurological input, we used an ex vivo vascular perfusion technique for glandular fluid secretion analysis. The surgical procedure was described previously (Romanenko et al., 2007; Nakamoto et al., 2008) . In brief, mice were anesthetized with chloral hydrate (400 mg/kg b.wt.), and the submandibular glands were dissected out under a dissecting microscope (SZX7; Olympus, Tokyo, Japan). The main artery was cannulated with a 31-to 32-gauge blunt-end cannula, and perfusion solution was applied with a peristaltic pump (IPC4; Ismatec, Glattbrugg, Switzerland) at a flow rate of 1 ml/min. The perfusion solution was composed of 120 mM NaCl, 4.3 mM KCl, 25 mM NaHCO 3 , 1.0 mM MgCl 2 , 1.0 mM CaCl 2 , 5 mM glucose, and 10 mM HEPES and was equilibrated with 95% O 2 -5% CO 2 . NaHCO 3 was replaced with the same concentration of NaCl to prepare a HCO 3 Ϫ removal solution and was equilibrated with 100% O 2 . Unlike CCh, CVL and PLC stimulated very little saliva secretion at 25°C (room temperature) in our preliminary experiments. Thus, the solutions and the glands were warmed at 37 Ϯ 0.5°C with a custom-made water jacket heating system. Fluid secretion was stimulated by adding each agonist at the indicated concentrations. Secreted saliva was collected by a precalibrated glass capillary tube, and the saliva flow inside the capillary was collected every 30 s for the first 3 min, and then every 1 min for the duration; the collected saliva was stored in 500-l tubes at Ϫ80°C until analyzed. The Na ϩ and Cl Ϫ concentrations in the saliva were analyzed with an electrode chip using DRI-CHEM 7000 (Fuji Film Medical, Tokyo, Japan).
Intracellular Signaling Measurements: Intracellular Ca

2؉
and pH. For cellular signaling, [Ca 2ϩ ] i and intracellular pH (pH i ) were measured. Submandibular glands were removed from anesthetized mice and placed in Krebs-Henseleit-Ringer solution (103 mM NaCl, 4.7 mM KCl, 25 mM NaHCO 3 , 2.8 mM glucose, 12.5 mM HEPES, 1.2 mM NaH 2 PO 4 , 4.9 mM sodium pyruvate, 2.7 mM sodium fumarate, 2.7 mM sodium glutamate, 2.6 mM CaCl 2 , and 1.1 mM MgCl 2 supplemented with 1 mg/ml bovine serum albumin), minced approximately 100 times with fine scissors, and then digested with 520 U/ml collagenase L (Nitta Gelatin, Osaka, Japan) for 20 min at 37°C with continuous shaking at 100 cycles/min. The digested tissue was washed three times and dispersed into 5 ml of Ringer's solution. The cells were incubated for 20 min with 1 to 2 M Fura-2 AM to detect [Ca 2ϩ ] i or 1 M 3Ј-O-acetyl-2Ј,7Ј-bis(carboxyethyl)-4(5)-carboxyfluorescein (BCECF), diacetoxymethyl ester to detect pH i . Fluorescence was detected under a microscope (IX71; Olympus) equipped with a fluorescence analysis system (Argus/ Aquacosmos; Hamamatsu Photonics, Hamamatsu, Japan), with excitation and emission wavelengths of 340 or 380 and 510 nm, respectively, for Fura-2 and 440 or 495 and 535 nm, respectively, for BCECF. The [Ca 2ϩ ] i was determined as the ratio of the emission at 380-nm excitation and emission at 340-nm excitation; the pH i was determined similarly for emissions at 495-and 440-nm excitation.
Drugs and Statistical Analysis. Pilocarpine was purchased from Nacalai Tesque (Kyoto, Japan). Collagenase L was from Nitta Gelatin. Fura-2 AM and BCECF, diacetoxymethyl ester were from Dojindo (Kumamoto, Japan). All other chemicals were purchased from Sigma Japan (Tokyo, Japan). Cevimeline was a gift from Nippon Kayaku (Tokyo, Japan).
The collected data are shown as mean Ϯ S.E. Student's t test was used for a comparison between two group means. For multiple comparisons, one-way ANOVA and then the Tukey post hoc test was applied to detect statistically significant differences using SPSS (version 14.0J; SPSS, Inc., Chicago, IL). Results were deemed significant at p Յ 0.05.
Results
Cevimeline-and Pilocarpine-Induced Salivation in
Mouse Submandibular Glands Ex Vivo. CVL and PLC are commonly used to induce fluid secretion in vivo, but few studies have examined the function of these agents ex vivo or in vitro. We examined the effects of these agonists in an in vitro system. At concentrations as low as 1 M, CVL was able to induce salivation in perfused mouse submandibular glands ex vivo. Stable salivation was observed using 10 M CVL [as well as 30 M (126.5 Ϯ 2.5 l/10 min, mean Ϯ S.E.)], and the kinetics of secretion during agonist stimulation was unchanged with up to nearly 1 mM CVL (Fig. 1A ). PLC at a concentration as low as 0.1 M induced salivation (1.5 Ϯ 0.8 l/10 min), and stable secretion was observed with approximately 3 M PLC (170.5 Ϯ 7.5 l/10 min) (Fig. 1B) . In addition, PLC was the most effective secretagogue during the 10 min of stimulation tested in this study (187.9 Ϯ 13.7 l/10 min at 10 M). CCh, a muscarinic agonist used experimentally, showed moderate secretion induction at 0.1 M, and stable secretion was observed at 0.3 M CCh (148.4 Ϯ 3.2 l/10 min) (Fig. 1C ). Higher concentrations of PLC induced salivation for a longer time period after removal of the agonist at 10 min, giving a greater total amount of secretion over a collection time of 20 min (Fig. 1E ) compared with CVL (Fig.  1D) or CCh (Fig. 1F) .
The kinetics of fluid secreted in response to PLC and CCh varied depending on concentration. At higher concentrations, secretion was biphasic, i.e., an initial rapid phase, followed by a lower plateau or gradual decrease (Fig. 1, B and C) . However, CVL lacked the initial peak phase (Fig. 1A) . Both PLC and CCh induced a rapid high flow rate in less than 1 min with strong stimulation at most concentrations tested, whereas CVL required approximately 3 min to reach the highest flow rate at all concentrations tested. Higher concentrations of PLC and CVL required 3 to 5 min to fully wash out their effects (Fig. 1, D and E) .
The analysis of Na ϩ and Cl Ϫ concentrations in secreted saliva revealed clear differences among the agonists. Compared with CVL, both PLC and CCh induced significantly higher Na ϩ concentrations in saliva (CVL versus PLC: p Ͻ (Fig. 1 , G-I). Whereas Na ϩ and Cl Ϫ contents changed depending on the PLC and CCh agonist concentration, they were unchanged in CVL saliva.
Effect of ␤-Agonist and Contribution of Epithelial Na ؉ Channels in CVL-, PLC-, and CCh-Induced Fluid Secretion. The Na ϩ and Cl Ϫ concentrations in mouse submandibular saliva are lower than those in parotid saliva, owing mainly to epithelial Na ϩ channels in the apical membrane of ductal cells . The cystic fibrosis transmembrane conductance regulator Cl Ϫ channel is critical for Cl Ϫ reabsorption in ductal cells (Catalá n et al., 2010) . Both mechanisms are up-regulated by phosphodiesterase, which can be pharmacologically activated by ␤-stimulation . Here, when 10 M isoproterenol (IPR) was added in the presence of a muscarinic agonist (30 M CVL, 3 M PLC, or 0.3 M CCh), the flow rate decreased slightly (Fig. 2 , A, C, and E), and the Na ϩ and Cl Ϫ concentrations decreased by ϳ50% for all agonists (Fig.  2 , B, D, and F).
We next examined whether the CVL-induced decrease in Na ϩ in saliva was attributable to specific activation of ENaC by using low concentrations of the inhibitor amiloride to specifically block ENaC. To ensure thorough inhibition of ENaCs, the glands were perfused with 10 M amiloride for 30 min before muscarinic stimulation (Catalá n et al., 2010) . Only the saliva of CVL-treated glands showed significantly increased Na ϩ levels in the presence of amiloride. Amiloride also blocked the IPR-induced increase in Na ϩ and Cl Ϫ absorption observed in the presence of all muscarinic agonists.
Effect of Muscarinic Agonists on [Ca 2؉ ] i and pH i . Because an increase in intracellular Ca 2ϩ is central to regulating fluid secretion, we hypothesized that differences in activities, especially initial secretion, among the agonists stem from differences in the ability to modulate cellular signaling. The induction of fluid secretion by CVL was much slower than that for the other agonists, but increases in Ca 2ϩ in the sustained phase did not differ significantly among the agonists (Fig. 3A) . Both CVL and PLC showed a slower decrease in [Ca 2ϩ ] i after removal of the agonist, and this was completely blocked by a muscarinic antagonist (0.5 M atropine) (Fig. 3B) .
With regard to pH i , both PLC and CCh induced a sustained decrease in pH i (Fig. 4, B and C) , whereas CVL at 30 M and higher concentrations (1 mM) produced only a minor change in pH i (Fig. 4A ). CVL showed a statistically significant, but minor, decrease in pH at maximal concentration (CVL versus PLC: p Ͻ 0.05; CVL versus CCh: p Ͻ 0.01). Melvin et al. (1988) revealed that stimulation with CCh acidified salivary cells and then the resting pH level recovers, which was accomplished by the Na ϩ /H ϩ exchanger. We hypothesized that CVL produces only a minor change in pH i because it specifically activates this exchanger. Several types of NHEs are expressed in salivary glands. NHE1 is the primary form, and it controls proton concentration in exocrine glands in both acinar and ductal cells (Evans et al., 1999; Brown et al., 2003) . Lower doses of 5-(N-ethyl-N-isopropyl) amiloride (EIPA) have been shown to specifically inhibit NHE1 (Orlowski and Kandasamy, 1996; Praetorius et al., 2000) . Perfusion of glands with 5 M EIPA for 2 min before muscarinic stimulation in the present study unmasked intracellular acidification, confirming that the reduced effect of CVL stimulation was due to its specific activation of NHE1 (Fig. 5A) . With the maximum drop in pH in the presence of EIPA, the differences among the agonists disappeared (Fig.  5, A-C) .
Anion accumulation from basolateral membranes and anion release at apical membranes are two main initiating components of saliva secretion. For continuous saliva flow, both the Na ϩ-K ϩ -2Cl Ϫ transporter and Cl Ϫ /HCO 3 Ϫ exchanger [anion exchanger (AE)] work together, coupled with NHE at the basolateral membrane (Evans et al., 2000; Melvin et al., 2005) . We confirmed the effect of NHE on fluid secretion by removing HCO 3 Ϫ from the external solution, which was accomplished by replacing NaHCO 3 with the same concentration of NaCl. The fluid in response to CVL decreased significantly (p Ͻ 0.01); however, that in response to PLC and CCh was not significantly different (Fig. 6 ).
Discussion
We explored the mechanistic differences among two clinically used muscarinic agonists, cevimeline and pilocarpine, and the experimentally used muscarinic agonist, carbachol (Fig. 1) . Both carbachol and pilocarpine showed different properties, depending on concentrations. At higher concentrations, they show a biphasic response, i.e., an initial transient high flow rate followed by decreased secretion. In comparison, cevimeline demonstrated slower induction of secretion at all concentrations tested and achieved stable secretion levels at higher doses. During the 10-min drug application, CVL and PLC induced sustained secretion over a very broad range of concentrations. CCh was capable of inducing fluid secretion over only a very narrow concentration range (0.3-1.0 M). We identified the lowest concentration at which we could detect stable secretion in response to 10 min Glands continued to secrete for several minutes after stimulation with CVL or PLC (and with higher concentrations of CCh), suggesting that these agents bind strongly to muscarinic receptors. This suggestion was confirmed by measuring [Ca 2ϩ ] i in vitro (Fig. 3) , which gave results consistent with those for ex vivo fluid secretion. The slow decay in [Ca 2ϩ ] i levels that was observed after removal of CVL or PLC was completely inhibited by atropine, producing a rapid return to resting [Ca 2ϩ ] i (Fig. 3B) . Furthermore, perfusion with 0.5 M atropine on muscarinic stimulation completely blocked ex vivo saliva secretion, indicating that CVL, PLC, and CCh induce salivation by activating muscarinic receptors (data not shown).
Compared with PLC and CCh, CVL treatment resulted in a significantly lower Na ϩ level in ex vivo saliva. There are at least three possible explanations for the significant Na ϩ decrease in ex vivo saliva in CVL-treated glands. First, Na ϩ absorption is flow rate-dependent; thus, the lower saliva flow rate observed with CVL relative to PLC and CCh may account for this difference. However, this possibility was eliminated by our tests on the effects of perfusion flow rate (data not shown). Decreasing the perfusion flow rate to 0.5 ml/min during exposure to 0.3 M CCh decreased the fluid secretion rate to approximately 20% less than that observed during perfusion with 30 M CVL at 1 ml/min, yet the Na ϩ concentration remained significantly lower in the CVL-induced saliva (42.6 Ϯ 2.1 mM Na ϩ for CVL versus 53.5 Ϯ 1.8 mM Na ϩ for CCh; p ϭ 0.002, Student's t test). Second, CVL may activate a Na ϩ reabsorption pathway, presumably NHE3, which is highly expressed on the apical membrane of salivary duct cells (Park et al., 2001 ). However, no change was observed in the Na ϩ levels of ex vivo parotid (Park et al., 2001 ) or in vivo submandibular (Catalá n et al., 2010) saliva from NHE3-gene disrupted mice, suggesting that NHE3-mediated Na ϩ absorption is probably not important at these flow rates. Finally, CVL may specifically activate ENaCs. We examined this possibility using amiloride, which inhibits ENaCs (Lingueglia et al., 1996) , but it also has other broad effects on membrane proteins in epithelial cells. We used amiloride at lower concentration (10 M) because it can inhibit not only ENaC but also NHEs at higher concentrations (Orlowski and Kandasamy, 1996; Praetorius et al., 2000) . Furthermore, the Na ϩ -dependent Ca 2ϩ transport mechanism (presumably the Na ϩ /Ca 2ϩ exchanger) was shown to be functionally expressed in the rat submandibular gland Morris et al., 1987) and may be affected by amiloride. However, replacement of external Na ϩ with Li ϩ to inhibit Na ϩ /Ca 2ϩ exchanger activity (Blaustein and Santiago, 1977; Laskowski and Medler, 2009) failed to show any significant change in [Ca 2ϩ ] i in response to CCh, suggesting that it may be present in mouse submandibular gland, but it is not functionally important during muscarinic stimulation (data not shown). In glands infused with amiloride starting 30 min before and during muscarinic stimulation, Na ϩ absorption was blocked significantly, and the differences among the agonists disappeared, indicating that ENaC activity increased in CVL-stimulated glands. The interaction between cystic fibrosis transmembrane conductance regulator and ENaC, which is discussed extensively elsewhere (Reddy and Quinton, 2003) , was made evident by treatment with a ␤-agonist (Fig. 2, B , D, and F), but the Na ϩ concentration was still significantly lowest in CVL, and ENaC inhibition abolished the differences in ion compositions among agonists. This finding suggests that the decreased Na ϩ concentration in CVL resulted from activation of ENaC, which was not associated with mechanisms involving ␤-agonists.
Unlike PLC and CCh, CVL produced minor intracellular acidification. Intracellular acidification during muscarinic receptor stimulation has been linked to up-regulation of NHE1, which is thought to be coupled with enhanced anion exchanger activity and increased fluid secretion. To determine whether CVL activated NHE, acinar cells were treated with EIPA, a specific inhibitor of NHE, in particular NHE1 (Orlowski and Kandasamy, 1996; Praetorius et al., 2000) . This maneuver revealed that in the presence of EIPA CVL produced a drop in pH i to a level similar to that induced by PLC and CCh. This result suggests that CVL rapidly enhanced the activity of NHE (presumably NHE1) during fluid secretion.
Removing the HCO 3 Ϫ from the external solution did not affect PLC and CCh ex vivo saliva, which was consistent with previously reported results in rats (Martinez, 1987) . On the contrary, HCO 3 Ϫ removal decreased CVL saliva significantly (Fig. 6 ), suggesting that a HCO 3 Ϫ -dependent Cl Ϫ /HCO 3 Ϫ exchange mechanism, which was coupled with NHE transport, was more active in the presence of CVL. Putative mechanisms discussed here are summarized in Fig. 7 . There are many reports on NHE activation, and an increase in [Ca 2ϩ ] i activates NHE exchange in salivary gland Turner, 1990, 1991) . Later the Ca 2ϩ -calmodulin complex was proposed to activate NHE, because no additional phosphorylation occurred in response to muscarinic stimulation in salivary gland (Robertson et al., 1997) . In addition, intracellular Na ϩ concentration sensing mechanisms have been discussed (Ishibashi et al., 1999) . In this study, it is likely that [Ca 2ϩ ] i alone was not involved in NHE up-regulation because we observed almost identical increases at both 30 M CVL and 3 M PLC (Figs. 3-5 ). In addition, we show that HCO 3 Ϫ may be involved in NHE activation mechanisms (Fig. 6) , consistent with previous reports (Yao et al., 1999) . However, HCO 3 Ϫ -involved mechanisms are extremely complex. HCO 3 Ϫ can pass through anion channels, it is transported by AE and Na ϩ -HCO 3 Ϫ cotransporters, and it can be produced by cellular metabolism by oxygen consumption and carbonic anhydrase (CA) (Li et al., 2006) . In addition, HCO 3 Ϫ transport is regulated as part of a so-called metabolon, in which NHE, CA, and AE interact (Gonzalez-Begne et al., 2007) . The activation mechanism by which CVL regulates the HCO 3 Ϫ -dependent pathway will be addressed in future studies.
